Back to Home
Featured

Promoting Evidence-Based Care and Health Equity in Endometrial Cancer Through Managed Care Interventions

August 10, 2022 | 7:00 PM ET

Countdown to Event

00

Days

00

Hours

00

Mins

00

Secs

Program Description

Endometrial cancer is the most common gynecologic malignancy in the United States. Primary prevention, early detection, and treatment have a large impact on patient outcomes. Unfortunately, disparities including biologic/genetic, behavioral, and social determinants affect patient access to care.  This activity will highlight the role of managed care professionals in caring for patients with endometrial cancer, specifically focusing on potential disparities in care. Additionally, the use of biomarkers to guide therapy selection will also be reviewed, with an emphasis on guideline-recommended treatment strategies.


Target audience: Health-system pharmacists, managed care pharmacists, oncology pharmacists

Type of activity: Application
Release date: August 10, 2022
Expiration date: October 10, 2022

Time to complete activity: 1.0 hour
Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

  • Explore the prognosis of metastatic endometrial cancer and the significance of biomarkers in determining appropriate therapy.
  • Investigate health equity issues affecting patients with endometrial cancer and the potential impact of disparities on clinical outcomes.
  • Interpret evidence-based guidelines and clinical trial data in the use of targeted therapies for the treatment of endometrial cancer.
  • Identify best practices for implementing evidence-based treatment to maximize cost-effectiveness of immunotherapies and mitigate the disparities in health equity for patients with endometrial cancer.